EMERYVILLE, Calif.--(BUSINESS WIRE)--Aug 30, 2018--Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system, today announced that new proof-of-concept preliminary data from its ongoing China clinical study evaluating ET140202 for the treatment of AFP-positive hepatocellular carcinoma (AFP+ HCC) will be presented as a late-breaking oral presentation at the 4 th Annual CAR-TCR Summit in Boston, Massachusetts, September 4-7, 2018.

The presentation details are listed below and are accessible on the 4 th Annual CAR-TCR Summit website:

Presentation Title: Case Report of Regression of Metastatic Liver Cancer After ET140202 T-Cell Therapy Session Title: Late Breaking Abstracts Date & Time: Wednesday, September 5, 2018 from 9:15 a.m. – 9:35 a.m. ET Location: Seaport Hotel & World Trade Center

Presentation Title: Improvement of Safety in T-cell Immunotherapies for the Treatment of Cancer Session Title: Overcoming CAR-T Toxicity in Solid Tumors (Agenda 1) Date & Time: Friday, September 7, 2018 from 1:00 p.m. – 1:30 p.m. ET Location: Seaport Hotel & World Trade Center

About Eureka Therapeutics, Inc.

Eureka Therapeutics, Inc. is a privately held clinical stage biopharmaceutical company focused on developing novel T-cell therapies that harness the evolutionary power of the immune system. Its core technology platforms center around its proprietary ARTEMIS™ T-cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of multiple solid and hematologic tumors.

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180830005236/en/

CONTACT: Eureka Therapeutics, Inc.

Natalie Liu, 510-722-8720

Investor Relations

natalie.liu@eurekainc.com

or

Stern Investor Relations

Julie Seidel, 212-362-1200

julie@sternir.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL

SOURCE: Eureka Therapeutics, Inc.

Copyright Business Wire 2018.

PUB: 08/30/2018 08:01 AM/DISC: 08/30/2018 08:01 AM

http://www.businesswire.com/news/home/20180830005236/en